
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is viewed favorably because its model now combines partner-funded development, recurring royalties, and commercial cash flow, reducing capital intensity while preserving upside from pipeline expansion. The FDA approval of Ziihera in 1L HER2-positive GEA, alongside HERIZON-GEA-01 data showing median PFS of 12.4 months versus 8.1 months and median OS of 26.4 months versus 19.2 months, materially de-risks the core asset and supports meaningful future royalty revenue. Additional support comes from a solid cash position of $572.5MM pro-forma, a $250M milestone payment, and advancing wholly owned programs such as ZW191 and ZW251.
Bears say
Zymeworks is viewed negatively because the bear case assumes zanidatamab’s commercial launch is underwhelming, which sharply reduces expected monetization from global royalties and milestones in BTC and GEA and eliminates any platform value. The company remains highly exposed to core biotech risks: clinical development failure, intense competition from existing and emerging therapies, and regulatory dependence on the FDA’s review pace and approval decisions. With a lower 10% probability of success in the royalty and milestone stream and a valuation framework that already supports only $15 fair value, the stock appears vulnerable to further downside if the program fails to deliver differentiated data or market traction.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zymeworks Inc (ZYME) Forecast
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares